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6/j.bHuman cytomegalovirus (CMV) reactivation and infection can lead to poor outcomes after allogeneic stem
cell transplantation. We hypothesized that anti-CD3 activated T cells (ATCs) armed with chemically hetero-
conjugated anti-CD3  polyclonal anti-CMV bispecific antibody (CMVBi) will target and eliminate CMV-
infected cells. Arming doses of CMVBi as low as 0.01 ng/106 ATCs was able to mediate specific cytotoxicity
(SC) directed at CMV-infected target cells significant above unarmed ATCs at mutiplicities of infection (MOI)
between 0.01 and 1. At effector-to-target ratios (E:T) of 25:1, 12.5:1, 6.25:1, and 3.125:1, armed ATCs sig-
nificantly enhanced killing of CMV-infected targets compared with unarmed ATCs. At an MOI of 1.0, the
mean % SC directed at CMV-infected targets cells for CMVBi-armed ATCs at E:T of 3.12, 6.25, and 12.5
were 79%, 81%, and 82%, respectively; whereas the mean % SC for unarmed ATCs at the same E:Twere
all\20%. ATCs, Cytogam, or CMVBi alone did not lyse uninfected or CMV-infected targets. Co-cultures
of CMVBi-armed ATCs with CMV-infected targets induced cytokine and chemokine release from armed
ATCs. This nonmajor histocompatibility complex restricted strategy for targeting CMV could be used to pre-
vent or treat CMV infections after allogeneic stem cell transplantation or organ transplantation.
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Immunotherapy, CytogamINTRODUCTION
Despite the use of appropriate antiviral agents,
cytomegalovirus (CMV) reactivation or infection limits
the success of allogenenic stem cell transplantation
(alloSCT) or organ transplantation. Reactivation of
CMV augments acute graft-versus-host disease
(GVHD) and is associated with organ rejection. Treat-
ment of GVHD with immunosuppressive agents en-
hances the vicious cycle of further CMV reactivation.
Most of the well-established strategies are not com-
pletely effective in preventing or treating CMV infec-ne Marrow Transplantation and Immunotherapy
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bmt.2012.01.022tions after transplantation, and vaccine strategies
against CMV infection have failed in immunocompro-
mised hosts and after alloSCT [1,2].
Post-alloSCT infusions of cloned donor CMV-
specific cytotoxic T lymphocytes (CTLs) have been
successful and encouraging [3,3-9] as have been
Epstein-Barr virus-specific CTLs for the treatment
of posttransplantation lymphoproliferative disease
[10-13]. But the logistics, cost, and labor intensity
involved in generating histocompatible virus-specific
CTLs remain challenging.
Numerous approaches have been tested or are
in development for amplification of CMV-specific
protective CTLs, nearly all of which depend on histo-
compatibility. The requirement for histocompatibility
eliminates the possibility for using CTLs from univer-
sal donors and leaves the daunting task of generating
either donor/recipient-specific CTLs or generating
sufficient numbers of amplified CTL populations to
provide coverage for a wide range of recipient HLA
profiles. Another difference is that HLA-matched
CTL approaches are based on the relatively restricted
array of CMV T cell epitopes in a given individual.
This study addresses the aforementioned challenge
and presents a novel approch to the clinical problem
through the use of a combination of existing immuno-
logic reagents. If successful, it would be a relatively
Biol Blood Marrow Transplant 18:1012-1022, 2012 1013Targeting CMV-Infected Cells with Armed T Cellssimple and high-impact approach to the treatment of
life-threatening CMV infections post-alloSCT. The
strategy takes advantage of the non-major histocom-
patibility complex-restricted, perforin/granzyme-
mediated cytotoxic properties of anti-CD3 activated
T cells (ATCs) by redirecting their cytotoxicity to
CMV-infected targets by arming ATCs with chemi-
cally heteroconjugated anti-CD3  anti-CMV bispe-
cific antibodies (CMVBi). We used polyclonal
Cytogam, which has the diverse array of HLA inde-
pendent anti-CMV antibody epitopes. This method
was adapted from the use of bispecific antibodies
(BiAbs) to retarget ATCs to tumors. Our earlier
studies showed that ATCs armed with anti-CD3 
anti-Her2/neu [14], anti-CD3  anti-CD20 [15], or
anti-CD3  anti-EGFR [16] BiAbs have high levels
of specific cytotoxicity directed at cancers of the breast
[14], prostate [17,18], colon, lung, head [16], and ova-
ries [19]. The BiAb retargeting approach enables es-
sentially every ATC in a population to specifically
target and kill cells bearing the antigen(s) of interest.
The activating end of the BiAb is a monoclonal anti-
body against CD3, which binds to and activates
CTLs; the arming end of the BiAb is an antibody
that can bind specifically to a tumor-associated antigen
or antigen(s) from bacterial or viral pathogens. In this
work, we take advantage of the diverse array of HLA-
independent anti-CMV antibody epitopes available in
the Cytogam IgG pool. CMVBi-armed ATCs could
be produced in 2 weeks from donors of bone marrow
transplantation recipients to prevent or treat CMV
disease using a similar approach.
Obviously, GVHD is a life-threatening concern
whenever donor-derived T cells are used in adoptive
transfer approaches. Bulk or polyclonally anti-CD3/
anti-CD28 coactivated donor T cells have been used
in combination with donor lymphocyte infusions in
patients without exacerbation of GVHD in patients
who had relapsed with hematologic malignancy [20],
and others have shown polarized CD41 type 2 cells
did not cause life-threatening GVHD [21]. We pres-
ent data in this study that suggests that activated T
cells may actually suppress allogeneic immune re-
sponses. This study asked the following questions:
(1) Can polyclonal human immune globulin enriched
in antibodies against CMV (Cytogam) be used to
produce chemically heteroconjugated anti-CD3 
anti-CMV bispecific antibodies that specifically target
and kill fibroblasts infected with CMV? (2)What is the
optimal arming dose of CMVBi for inducing specific
cytotoxicity and optimal time to harvest ATCs for op-
timal CMV-specific cytotoxicity? (3) Will CMVBi-
armed ATCs secrete Th1 cytokines and chemokines
upon engagement with CMV-infected target cells?
(4) Will CMVBi-armed ATCs cause or augment
GVHD in the alloSCT setting? The results of this pre-
clinical study show that healthy related or unrelateddonor anti-CD3 activated T cells can be armed with
very low doses of CMVBi to specifically kill CMV-
infected cells. CMVBi-armed ATCs secrete cytokines
and chemokines upon engaging infected targets and
exhibit low levels of alloreactivity. Our results support
the feasibility of clinical trials of CMVBi-armed ATCs
to prevent or treat CMV in hematopoietic stem cell or
solid-organ transplantations.MATERIALS AND METHODS
Blood and Perpheral Blood Mononuclear Cell
Separation
Perpheral BloodMononuclear Cells (PBMCs) were
isolated fromheparinizedwholebloodofnormalhealthy
donors by Ficoll-hypaque density gradient centrifuga-
tion and resuspended in RPMI-1640 (Lonza, Inc.,
Allendale, NJ) supplemented with 10% FCS (Lonza),
L-glutamine (Lonza), and penicillin-streptomycin
(Lonza). The Wayne State University institutional re-
view board approved research protocols for blood col-
lection. All blood donors signed consent forms.
Cells and Virus
A human lung fibroblast cell line (MRC-5)
was maintained in RPMI-1640 culture medium
supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, and antibiotics. These cells were infected
with a green fluorescent protein-expressing version of
CMV strain (AD169) at various multiplicities of infec-
tion (MOI) ranging from 0.01 to 1.
Expansion and Generation of ATC
PBMCs were expanded using 20 ng/mL of OKT3
and 100 IU of IL-2 for 14 days at a concentration of
1  106 PBMC/mL in RPMI-1640 supplemented with
10% fetal bovine serum. Cells were maintained at 1 
106 cells/mL, and 100 IU/mL IL-2 was added every 2
to 3 days throughout the initial culture period. ATCs
were either used fresh or cryopreserved for later use.
Production of Anti-OKT3  Anti-CMVBi
Antibodies
BiAb were produced by chemical heteroconjuga-
tion of OKT3 (a murine IgG2a anti-CD3 monoclonal
antibody; Ortho Biotech, Horsham, PA) and
Cytogam (CSL Behring, King of Prussia, PA), as de-
scribed previously using Trauts reagent to crosslink
OKT3 and Sulfo-SMCC to cross-link Cytogam [15].
Cytogam is a pooled CMV-specific human IgG al-
ready approved for routine clinical use by the FDA.
In the initial experiments, ATCs were armed using
an arbitrarily selected concentration of BiAb (50 ng/
106 ATCs) for 30 minutes with either CMVBi or irrel-
evant anti-CD3  anti-CD33 bispecific antibody
(CD33Bi) to verify that CMVBi-armed ATCs would
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Following arming, armed ATCs were washed thrice
to eliminate any unbound BiAb before use in these
experiments.
Immunofluorescence Microscopy
CMV-infected human lung fibroblasts fixed on
slides (MBL-BION, Des Plaines, IL) were permeabi-
lized in phosphate-buffered saline (PBS) containing
0.2% Triton X-100 and 10% normal goat serum for
15 min followed by incubation for 1 hour in blocking
buffer (10% normal goat serum and 5% glycine in
PBS). Permeabilized and blocked CMV- infected cells
were incubated for 1 hour at room temperature with
primary antibodies (CMVBi, anti-CMV immediate
early protein 2 [anti-IE-2], Cytogam, anti-CD3 
anti-CD20 [CD20Bi]) diluted in blocking buffer. Cells
were then washed 3 times with PBS and allowed to re-
act for 1 hour with similarly prepared corresponding
secondary antibody (goat antihuman IgG-PE was
used to detect Cytogam or Cytogam arm of the
CMVBi, goat antimouse IgG-FITCwas used to detect
anti-IE2). At the end of the incubation, cells were
washed and mounted using Vectashield with 40,6-
diamidino-2-phenylindole (DAPI) (Vector Laborato-
ries, Burlingame, CA). Images were captured with
a Leica TCS-SP digital confocal microscope.
Cytotoxicity Assay
Cytotoxic activity of ATCs or CMVBi-armed
ATCs to CMV-infected fibroblasts (targets) was eval-
uated to assess the specific and nonspecific target
killing by chromium (51Cr) release assay in 96-well
flat-bottomedmicrotiter plates as previously described
[14]. Briefly, ATCs or ATCs armed with CMVBi were
plated in triplicate onto 51CR-loaded target cells (4 
104 cells/well) at E:T ratio of 25:1, 12.5:1, 6.25:1, and
3.12:1. 51Cr release was measured after 18 hours, and
percent cytotoxicity was calculated using the following
formula: (experimental cpm 2 spontaneous cpm)/
(maximum cpm 2 spontaneous cpm)  100%.
Mixed Lymphocyte Cultures
PBMC from the responder and unarmed ATCs or
armed ATCs derived from the responder were stimu-
lated with irradiated autologous PBMC or the irradi-
ated allogeneic PBMC. All cocultures contained
100,000 responders and 100,000 irradiated stimula-
tors. Cells were irradiated with 2,500 rads using a
Cesium2 source. Proliferative responses were mea-
sured byCellTiter-GloLuminescentCell Viability As-
say (Promega,Madison,WI).The assay determines the
number of viable cells in cultures based on quantitation
of the ATPs present, which signal the presence of met-
abolically active cells. The number of viable cells serves
as a surrogate marker for proliferation in the mixed
lymphocyte cultures. In order to compare experiments,the various cocultures were normalized to the alloge-
neic control culture: PBMC responder (Pr)  alloge-
neic PBMC irradiated stimulator (P*s) 5 100%.
Cytokine Profiling of Cocultures
Cytokines were quantitated in culture superna-
tants collected from CMV-infected or uninfected
MRC-5 cells with ATCs or CMVBi-armed ATCs
cocultures using a 25-plex human cytokine Luminex
Array (Invitrogen, Carlsbad, CA) on a Bio-Plex system
(Bio-Rad Lab, Hercules, CA). The limit of detection
for these assays is\10 pg/mL based on detectable sig-
nal of .two fold above background (Bio-Rad). Cyto-
kine concentrations were automatically calculated by
the BioPlex Manager Software (Bio-Rad).
Statistical Methods
Descriptive statistics (means, ranges, and SD) were
used to analyze most data sets. Comparison of paired
data between groups was performed using nonpara-
metric Wilcoxon rank-sum test. All P values are two
sided, with P\ .05 considered statistically significant.
All of the analyses were performed using SigmaStat
Version 3.5 (2006 Systat Software, Chicago, IL).RESULTS
Characterization of the ATCs
ATCs that were grown for 14 days expanded
ameanof 106five fold (n5 10)withmeanproportions
ofCD315 95%,CD415 20%6 10, CD815 60%6
10, CD45RA2/CD45RO1 5 70 6 10, CD251/
CD41/CD1272 52.5 6 2, CD251/CD81 5 2 6 1.5.
Production of CMVBi
CMVBi was produced by chemical heteroconju-
gating OKT3 and Cytogam as previously described
[14], and the proportion of monomers, dimers, and
multimers was characterized in a nonreducing PAGE
gel (Figure 1A). CMVBi (lane 3) shows distinct bands
of monomeric unconjugated OKT3 and Cytogam,
plus dimers and multimers of CMVBi. The product
contains approximately 30% dimer, 52% unconju-
gated monomers, and 18% multimers. These results
are comparable to the proportions seen in the conjuga-
tion of other bispecific antibodies.
CMVBi Binds to Cell Surface, Cytoplasmic, and
Nuclear Viral Antigens
We determined whether CMVBi retained the abil-
ity to bind CMV viral antigens on infected target cells
(Figure 1B). CMV-infected cells stained with anti-
CMV IE-2 (FITC-labeled secondary antibody) and
CMVBi (PE-labeled secondary antibody). The cells
were then counterstained with the nuclear stain
Figure 1. (A) Production of CMVBi.OKT3 was cross-linked with Traut’s reagent, and Cytogam was cross-linked with SMCC before mixing followed
by overnight heterconjugation. The reactants were resolved by nonreducing PAGE gel and stained with Coomassie blue. All lanes were loaded with 8 mg
of protein. Lane 1: OKT3; lane 2: Cytogam; lane 3: CMVBi. (B) Staining of CMV-infected cells.The series of panels show dual staining for infected fibro-
blasts by staining for IE-2 (FITC, green) expressed in the nucleus, cytoplasm, and cell surface viral proteins by staining with CMVBi (PE, red). Nuclei of
infected and noninfected cells were counterstained with blue DAPI (blue, lower left panel). The rightlower panel shows merged images for anti-IE2 and
anti-CMVBi staining at 20 magnification.
Figure 2. Cytotoxicity directed at CMV-infected MRC-5 fibroblasts as
a function of the CMVBi arming dose. Cytotoxicity mediated by ATCs
armed with increasing doses of CMVBi directed at MRC-5 human lung
fibroblasts infected with CMV strain AD169. ATCs were armed with
0.01, 0.1, 1, 5, 50, 100, and 200 ng per 106 ATCs and tested for specific
cytotoxicity against CMV-infected cells with anMOI of 0.1 after 96 hours
of infection. Unarmed ATCs from the same normal donor are shown.
The data represent the mean cytotoxicity 6 standard error of the
mean (SEM) of triplicate determinations.
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cent microscopy revealed strong anti-IE2 nuclear
staining in most cells, demonstrating CMV infection.
Staining with CMVBi or Cytogam showed surface
and cytoplasmic staining of CMV-infected cells with
little background staining in uninfected cells by either
CMVBi or Cytogam. Low-level CMVBi or Cyto-
gam staining in some IE2-positive cells suggests
that the antibodies in CMVBi and Cytogam target
genes expressed late in the CMV replication cycle.
CMVBi Arming Dose Titration
To determine the optimal arming dose, ATCs
were armed with increasing doses of CMVBi ranging
from 0.01 ng to 200 ng of CMVBi/106 ATCs. The
dose titration curve showed arming doses as low as
0.01 ng of CMVBi/106 ATCs could mediate 33%
specific cytotoxicity, while maximum cytotoxicity
(39%) at the same E:T of 12.5:1 was observed at 50
ng of CMVBi/106 ATCs against CMV-infected
MRC-5 at anMOI of 0.1 (Figure 2). Based on the titra-
tion dose response curve shown in Figure 2 (represen-
tative of 3 separate individuals), a dose of 50 ng/106
ATCs was chosen for all subsequent experiments.
Fresh and cryopreserved ATCs exhibited comparable
specific cytotoxicity when armed before or after cyro-
preservation. Different E:T ratios, ranging from
3.125:1 to 25:1, were tested to delineate the specific cy-
totoxicity curve as a function of the E:T ratio. Because
approximately 40% of the heterconjugate was active in
binding with a 20% arming efficiency (based on the gel
scans in Figure 1A), ATCs armed with 0.01 ng of
CMVBi per 106 ATCs would bear 2 106 IgG mol-
ecules on the surface of each cell. Furthermore, assum-
ing 10 or 1% of the IgG were CMV specific, 200 or
20  103 CMV-specific IgG molecules would theo-
retically be bound to the surface of a single T cell.
As a negative control, we tested ATCs armed withanti-CD3  anti-CD33 BiAb for cytotoxicity directed
at CMV-infected or noninfected MRC-5. The level of
cytotoxicity is seen at levels equivalent to unarmed
ATCs alone (data not shown).Kinetics of CMV Infection for Optimal
Cytotoxicity
The development of cytotoxicity was measured at
48, 72, and 96 hours after CMV infection at a MOI
of 0.1. Cytotoxicity mediated by CMVBi-armed
ATCs as a function of CMV infection (Figure 3).
Peak cytotoxicity mediated by CMVBi-armed ATCs
from 3 donors occurred at 96 hours after CMV infec-
tion in Figure 3 (bottom panel). This suggests that
viral late genes are important targets for the cytotoxic
reaction and provide further evidence of the specificity
Figure 3. Cytotoxicity as a function of time of CMV infection. CMVBi-
armed ATCs and unarmed ATCs from one donor were tested against
MRC-5 targets at E:T from 3.12 to 25:1 at 48, 72, and 96 hours after in-
fection at an MOI of 0.1. The data are presented as mean6 SEM of trip-
licate determinations.
1016 Biol Blood Marrow Transplant 18:1012-1022, 2012L. G. Lum et al.of the reaction. Unarmed ATCs did not lyse CMV-
infected fibroblasts.
Cytotoxicity of CMV-Infected Targets Increases
with Increase in MOI
MRC-5 cells were infected with the AD169 strain
of CMV atMOI ranging from 0.01 to 1.0 to determine
the interaction between MOI and the E:T ratio for cy-totoxicity mediated by the CMVBi-armed ATCs. Un-
infected MRC-5 and MRC-5 infected with AD169
strain of CMV at MOI ranging from 0.01 to 1 were
plated in 96-well plates at a concentration of 40,000
cells/well for 96 hours postinfection. Normal donor
ATCs unarmed and armed with CMVBi at 50 ng/106
ATCs were added to 96-well plates to MRC-5 targets
that were labeled with 51Cr for 4 hours, at E:T ranging
from 3.125 to 25:1. As shown in Figure 4, as the MOI
increased, so did the percentage of specific cytotoxicity
mediated by armed ATCs, whereas cytotoxicity medi-
ated by unarmed ATCs did not increase. This experi-
ment shows that killing of CMV-infected fibroblasts
also increases as a function of the increased number
of CMV-infected targets in the pool. Neither unarmed
nor CMVBi-armed ATCs were able to kill uninfected
fibroblasts at any of the MOIs. It is important to note
that most published studies of CTL killing of CMV-
infected cells used a much higher MOI of 5 [7]. These
results suggest that CMVBi-armed ATCs are remark-
ably effective at specifically targeting the scattered
infected cells in cultures at low MOI. Based on the
data in Figure 3, we used CMV targets that were in-
fected for 96 hours at anMOI of 0.1 for subsequent ex-
periments unless otherwise specified.
Cytotoxicity Mediated by CMVBi-armed ATCs
from High to Low E:T
In this set of experiments, we asked whether
CMVBi-armed ATCs can mediate the cytotoxicity at
lowE:T. CMVBi-armed ATCc and ATCc from 3 nor-
mal donors were tested at an MOI of 0.1 at 96 hours of
CMV exposure at a range of E:T from 25:1 down to
0.125:1 (1:8) (Figure 5A). The mean cytotoxicity ex-
hibited by armed ATCs was consistently higher than
ATCs at all E:T ratios. More intriguingly, E:T as
low as 1:1 showed 8% to 20% killing of specific targets.
These data clearly show that CMVBi-armed ATCs are
highly effective cytotoxic effector cells that are capable
of lysing multiple CMV-infected targets at a low E:T
ratio.
CMVBi-Armed ATCs Cytotoxicity Is Not
Because of Antibody-Dependent Cell-Mediated
Cytotoxicity or Complement-Mediated
Cytotoxicity
In order to determine if Antibody-Dependent
Cell-Mediated Cytotoxicity (ADCC) or Complement-
Mediated Cytotoxicity (CDC) of Cytogam or
CMVBi would mediate comparable cytotoxicty to
CMVBi-armed ATCs. CMV-infected MRC-5 cells
were cocultured with Cytogam or CMVBi alone in
the presence of PBMC or human complement
(Figure 5B). Fresh PBMCor fresh human complement
were added to test ADCC or CDC, respectively,
against CMV-infected targets. Cytogam and CMVBi
Figure 4. CMVBi-armed ATCs targeting of CMV-infected and uninfected fibroblast as a function MOI. MRC-5 human lung fibroblasts were plated after
infected for 96 hours (I) at the MOIs of 0.01, 0.05, 0.1 and 1.0 or left uninfected as controls (UnI) as indicated in each panel. ATC-I (ATCs 1 infected
targets), armed ATC-I (CMVBi-armed ATCs 1 infected targets); ATC-UnI (ATCs1 unInfected targets); and armed ATC-UnI (CMVBi-armed ATCs1
uninfected targets).
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complement) did not kill CMV-infected targets (\1%
cytotoxicity), whereas CMVBi or Cytogram in the
presence of PBMC exhibited 0% to 24% and 1.2 to
35% ADCC, respectively. These data were compared
with armed and unarmed ATCs from 2 normal sub-
jects at E:T from 25 to 3.125:1 (Figure 5B). CMVBi-
armed ATCs exhibited high levels of specific cytotox-
icity ranging from 70% to 100% at E:T from 25:1 to
3.125:1 at an MOI of 1.0.
Radioresistant Cytotoxicity Mediated by
CMVBi-Armed ATCs
Because CMVBi-armed ATCs may respond to
alloantigens, CMVBi-armed ATCs were tested to de-
termine whether they would exhibit CMV-specific
cytotoxicity after 2,500 rad of irradiation. Specific cy-
totoxicity mediated by irradiated (*) CMVBi-armed
ATCs was comparable to the cytotoxicity directed at
CMV-infected fibroblasts by unirradiated CMVBi-
armed ATCs from 2 separate individuals. Irradiated
and unirradiated unarmed ATCs did not exhibit cyto-
toxicity (Figure 5C).
Interferon-gamma, Macrophase Inflammatory
Protein 1-alpha, and MIP-1b Secreted by
CMVBi-Armed ATCs
Because in vitro targeting of breast cancer with
anti-CD3  anti-Her2/neu BiAb or lymphoma with
anti-CD3  anti-CD20 BiAb triggers a Th1 patternof chemokine secretion from ATCs [14,15], we
tested whether armed ATCs would secrete cytokines
upon engaging CMV-infected targets. CMVBi-
armed ATCs from 2 normal individuals were co-cul-
tured with CMV-infected or uninfected targets for
24 hours at a 10:1 E:T and an MOI of 0.1. Cytokine
concentration was adjusted to pg/106 armed or un-
armed ATCs. Culture supernatants from cocultures
of armed ATCs with CMV-infected fibroblasts
showed an average of 6-fold more interferon-gamma
(IFN-g), 15-fold more macrophase inflammatory pro-
tein 1-alpha (MIP-1a), and 31-fold more MIP-1b than
cocultures of ATCs and infected fibroblasts. Themean
absolute increments in pg/mL/106 cells were 128,
1,167, and 3,031 pg/mL for IFN-g, MIP-1a, and
MIP-1b, respectively (Table 1). Uninfected fibroblasts
cocultured with ATCs had mean background levels
of 26 pg/mL for IFN-g, 293 pg/mL for MIP-1a, and
440 pg/mL for MIP-1b (data not shown).Depressed Mixed Lymphocyte Culture
Responses
Mixed lymphocyte culture responses (MLRs) of
CMVBi-armed ATCs were tested to determine
whether random or non–HLA-matched normal donor
samples could respond to host alloantigens in patients
undergoing organ or alloSCT. Both ATCs and
CMVBi-armed ATCs showed depressed allogeneic re-
sponses in MLR in 6 unrelated responder and stimula-
tion combinations tested (Figure 6). The allogeneic
Figure 5. (A) Specific cytotoxicity directed at CMV-infected fibroblasts
at various E:T ratios. CMVBi-armed ATCs (aATC) and unarmed ATCs
(ATC) from 4 donors were tested for cytotoxicity-directed MRC-5 tar-
gets at an MOI of 0.1 at E:T from 25:1 to 0.125:1 in 51Cr release cyto-
toxicity. The data are presented as the mean 6 SEM of 4 donors. (B)
Comparison of cytotoxicity seen in ADCC, CDC, and CMVBi with
ATCs and armed ATCs. PBMC or ATCs from 2 normal subjects were
used for this experiment. Antibody-dependent cellular cytotoxicity
was tested using CMVBi at 50 ng/mL (CMVBi-ADCC) and Cytogam
10 mg/mL (Cytogam-ADCC) in the presence of fresh PBMC at the
Table 1. IFN-g, MIP-1a, and MIP-1b Secretion (pg/mL/24
hours/106)
Culture Conditions IFN-g MIP1a MIP1b
Infected targets + ATC1 14 133 84
Infected targets + ATC2 38 31 116
Mean infected targets + ATC 26 82 100
Infected targets + CMVBi-armed ATC1 202 2250 5335
Infected targets + CMVBi-armed ATC2 105 248 926
Mean infected targeted + armed ATC 154 1249 3131
Net mean increment in secretion 128 1167 3031
ATC1 and ATC2 indicate 2 normal subjects; infected targets, CMV-
infected fibroblasts, MOI 0.1 at 96 hours after infection; net mean incre-
ment, amount produced by CMVBi-armed ATCs above the amount
produced by ATC.
Single determinations were performed for each data point. The bioplex
system has been consistently reproducible on standards with 610 pg.
1018 Biol Blood Marrow Transplant 18:1012-1022, 2012L. G. Lum et al.response to alloantigens by unarmed ATCs was (26.7)
73% less than the allogeneic MLR control (P 5 .002,
n 5 6, Mann-Whitney rank-sum test) and the alloge-
neic response to alloantigens by armed ATCs was
(24.1) 75.9% less than the allogeneic MLR control
(P5 .002, n5 6). There was no difference in the allo-
geneic responses between unarmed and armed ATCs
(P 5 .07).DISCUSSION
Adoptive immunotherapy using antigen-specific
CTL to treat patients with CMV viral infection needs
to be safe, effective, easily reproduced, and transport-
able. This new approach for manufacturing CMV-
specific cytotoxic T lymphocytes incorporates these
elements for rapid translation to the clinic. This study
shows that polyclonal anti-CMV IgG can be used to
produce CMVBi for arming ATCs to specifically tar-
get and lyse CMV-infected fibroblasts. CMVBi specif-
ically bound to T cells and CMV antigens and cell
membranes of CMV-infected fibroblasts at an optimal
dose of 50 ng/106 ATC. Binding of the armed ATCs to
CMV-infected targets triggered secretion of IFN-g,
MIP1-a, and MIP1-b. Irradiation of armed ATCs to
eliminate allogeneic proliferative responses did not
impair cytotoxicity, and armed ATCs did not respond
to allo-antigens.
Since the initial approach to expand antigen-specific
T cells using anti-CD3 and CMV antigen [3,6,22],indicated E:T, ATCs armed with 50 ng/106 ATCs (CMVBi-armed ATCs)
or unarmed ATCs (ATC) were tested for cytotoxicity at the indicated
E:T. Complement-dependent cytotoxicity (CDC) was tested using fresh
human complement (1:10 dilutions of fresh human serum) either in the
presence of CMVBi at 50 ng/mL or Cytogam 10 mg/mL on MRC-5 tar-
gets. The experiments were conducted at anMOI of 1. (C) The effects of
irradiation on cytotoxicity mediated by CMVBi-armed ATCs. Unarmed
ATCs (ATC), CMVBi-armed ATCs (aATC) from 2 donors were tested
against irradiated ATCs (ATC*) and irradiated CMVBi-armed ATCs
(aATC* for specific cytotoxicity directed at CMV-infected fibroblasts)
(0.1 MOI after 96 hours of infection) at E:T from 3.12 to 25:1. The
data are presented as mean 6 SEM of triplicate determinations.
Figure 6. Marked depressed allogeneic responses from ATCs and
armed ATCs. Six experiments involving cocultures of unrelated alloge-
neic responder PBMC (Pr) and irradiated PBMC stimulator cells (P*s)
in the allogeneic MLR control. Pr and autologous irradiated PBMC
(P*r) from the same individual cocultured in an autologous MLR; ATCs
from the responder (ATCr) cocultured with autologous P*r in an autol-
ogous MLR (control); ATCr cocultured with P*s in allogeneic MLR to
assess allo-reactivity of ATC; responder armed ATCs (aATCr) cocultured
with autologous P*r in an autologous MLR (control); and aATCr cocul-
tured with P*s in allogeneic MLR to assess allo-reactivity of aATC.
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producting CMV-specific CTL [23-39]. Despite these
extensive preclinical experiments, only a few
approaches have reached clinical trials [3,40] because
of applicability. Our platform of customizable BiAb
production from pooled human sera and the proven
feasibility of clinical-scale manufacturing of T cells
allows us to target the broadly relevant epitopes exp-
ressed on the CMV-infected cells.
This study shows that a polyclonal CMVBi can be
produced, and very low doses (0.01 ng/106 ATC) can
be used to arm ex vivo expanded ATCs that can then
specifically target and kill CMV-infected fibroblasts
at low E:T and at low and high MOI without nonspe-
cific cytotoxicity. Such a high level of specific cytotox-
icity might have been unexpected from a polyclonal
bispecific antibody construct because only a fraction
of the total Ig in Cytogam (already enriched for
anti-CMV activity in the manufacturing) may be
CMV specific. Assuming that only 5% to 10% of poly-
clonal Cytogam is CMV specific, our CMVBimay be
at least as potent on a per/ng basis than a BiAb derived
from a CMV monoclonal antibody. Unfortunately,
there are no clinical grade anti-CMV mAbs that could
be used for this approach. In our prior studies using
anti-CD3  anti-Her2 BiAb, we found that the dimer
and multimer fractions from a size fractionation col-
umn mediated high levels of comparable cytotoxicity
directed at breast cancer cell lines, while the monomer
fraction lacked specific cytotoxicity. Because theunfractionated material turned out to be so potent,
we did not affinity purify the CMV-specific antibodies
from Cytogam.
It is not clear how many CMV antigens or which
CMV antigens need to be expressed on the surface of
the CMV-infected fibroblasts or other cells lines (eg,
endothelial cells) to achieve the threshold for binding
with the armed ATCs to trigger target lysis mediated
by granzyme B. If CMV targeting is analogous to
that seen inHer2Bi ATCs targeting of cancer cells lines
(low Her2 expressing MCF-7 breast cancer or PC-3
prostate cancer), then only low-level expression of viral
antigens may be required to achieve the targeting and
cytotoxicity threshold. Additional studies are under-
way to assess the ability of CMVBi-armed ATCs to
recognize clinical strains of CMV and to kill other
types of CMV-infected cells (eg, endothelial cells).
Our studies show thatHer2Bi-armed ATCs are ca-
pable of high levels of cytotoxicity directed at MCF-7
(breast cancer line) that express nearly undetectable
levels of Her2 receptors (less than 5-10  103 Her2)
[14]. ATCs armed with Her2Bi can target Her2-
positive cells, and Her2Bi-armed ATCs can kill multi-
ple target cells, divide and secrete IFN-g, tumor
necrosis factor-alpha, granulocyte macrophage col-
ony-stimulating factor, and chemokines after engaging
Her2/neu tumor targets in vitro [41]. Cytokines se-
creted by armed ATCs (eg, IL-2, granulocyte macro-
phage colony-stimulating factor, and chemokines
such as RANTES, and MIP-1a) at the tumor site
may provide an in vivo milieu conducive to induction
of an endogenous immune response to tumor antigens.
Furthermore, the armed ATCs are able to mediate re-
peated cycles of cytotoxicity and cytokine/chemokine
secretion upon repeated T cell engagement with new
tumor cells [41]. Therefore, infusions of autologous
CMVBi armed ATCs may not only act as a antiviral
agent to kill CMV-infected targets but can also divide,
proliferate, secrete cytokines/chemokines, and kill
multiple CMV-infected targets.
Arming ATCs with CMVBi may circumvent some
of the potential major limitations of infusing CMVBi
alone, which could lead to cytokine storm mediated
by binding of the BiAb to Fc-R bearing natural killer
cells, monocytes, and mast cells [42]. Cytokine storm
with dose-limiting toxicities has been observed in
nearly all infusions of BiAb alone and keep BiAbs
from clinical development. The in vitro cytotoxicity
mediated by armed ATCs is clearly superior
to CMVBi in complement-mediated cytotoxicity
or ADCC. Use of polyclonal CMV-specific IgG
(Cytogam) as a component of CMVBi may enable
ATC targeting of multiple CMV antigens that would
not be recognized by single mAb. The broad reper-
toire of naturally occurring IgG anti-CMV antibodies
in the Cytogam pool represents the range of naturally
occurring human immune responses against CMV.
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CMV antigens that have not been recognized or for
which humanized mAb are not available. Polyclonal
targeting may result in marked improvement in the
clinical management of CMV infections after alloSCT
or organ transplantation. This strategy may also be ap-
plicable to treatment of Epstein-Barr virus, herpes
simplex virus, and BK virus infections.
The downside of using a polyclonal antiserum
from normal donors that include women who have
been pregnant is the potential of exacerbating GVHD
because of antibodies directed at paternal antigens
that are present in any preparation of human poly-
clonal immunoglobulin preparation (eg, intravenous
immunoglobulin or Cytogam) is a theoretical con-
cern. In clinical trials of intravenous immunoglobulin
to prevent infectious complications after alloSCTs or
Cytogam in combination with ganciclovir for the
treatment of CMV, increased incidence or severity of
GVHD were not observed.
The repertoire of anti-CMV antibodies in Cyto-
gam preparation will vary, leading to batch-to-batch
variation of CMVBi produced for clinical trials. In or-
der to adjust for the specific CMV toxicity exhibited by
the armed ATC product, each lot of CMVBi will be
titered for specific cytotoxicity directed at specific
and nonspecific targets. A major barrier to application
of CTL therapies to treatment of CMV infections is
that donor-derived CTL may cause life-threathening
GVHD. Therefore, strategies to deplete alloreactive
cells or control the allogeneic response need to be in-
corporated into approaches that employ nonautolo-
gous products. Irradiated ATCs can mediate specific
CMV cytotoxicity but lack of responses to alloanti-
gens, which makes it possible to produce ATCs from
healthy HLA matched or mismatched donors to pro-
duce ATCs. One approach would involve infusing un-
related matched or partially matched-irradiated armed
ATCs to treat CMV infections. This would be a uni-
versal ‘‘soldiers’’ armed anti-CMV T cell product
that could be produced, cryopreserved in multiple ali-
quots for multiple infusions, and thawed as needed.
These ‘‘presuicide’’ or irradiated universal soldiers
would not allow proliferation of the CMVBi armed
ATCs to potentiate GVHD.
The second approach would be to use unirradiated
ATCs that we have shown to consistently not respond
to alloantigens. Because the MLR studies involved
randomly selected donor:stimulator pairs, they may
have significant HLA disparities. Both armed and un-
armed ATCs exhibited mean responses\20% of the
allostimulated control cultures indicating a lack of re-
sponsivness. We anticipate that the alloreactivity by
ATCs from HLA-identical sibling donors should be
no more than the low levels seen in our in vitro studies
using HLA-disparate cells. A murine study using
anti-CD3 activated donor T cells had a reduced abilityto cause lethal murine GVHD but retained their abil-
ity to facilitate alloengraftment [43]. A possible expla-
nation for the ‘‘lack of response’’ in our systems is that
nonspecific polyclonal activation with anti-CD3 in the
absence of nominal antigens expanded clones nonspe-
cifically and, therefore, by 14 days of culture, the pre-
cursor frequency of allo reactive clones that can
develop an alloresponse have been overgrown or
suppressed by regulatory cells generated in the ATC
culture.
In summary, our strategy of using cryopreserved
HLA-identical donor T cells or unrelated donor T
cells armed with CMVBi to target CMV-infected cells
in a nonmajor histocompatibility complex-restricted
manner offers the possibility of a straightforward and
inexpensive method for producing ‘‘polyclonal’’ CTL
directed at multiple CMV antigens from related or un-
related donor T cells. The strategy eliminates the 2
weeks or more required for generation of infusible his-
tocompatible CMV-specific T cell clones. If armed
ATCs do not augment the rate of GVHD in phase I
trials, phase II trials could be conducted to determine
whether multiple infusions of CMVBi armed could be
used as a prophylaxis or to treatment when there is
a rise in CMV viral load. The cost of production is es-
timated at $5,000 per 80 billion CMVBi-armed ATCs,
including cost of labor, antibodies, media, plasticware,
bioreactor bags, and quality-control release testing.
Based on our experience, armed ATC infusions per
se are not likely to have dose-limiting toxicities. Our
data strongly support evaluation of CMVBi-armed
ATCs in phase I/II clinical trials to treat patients
CMV infections in allogeneic SCT or organ transplan-
tation recipients.ACKNOWLEDGMENTS
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